Literature DB >> 12943488

Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis.

Eric Schenkel1.   

Abstract

Mometasone furoate aqueous nasal spray (NS; Nasonex, Schering Corporation), is a synthetic corticosteroid approved for the prophylaxis and treatment of seasonal allergic rhinitis (SAR) and the treatment of perennial allergic rhinitis (PAR) in patients >or= 12 years of age, and for the treatment of SAR and PAR in children as young as 2 years of age. Studies demonstrate that mometasone furoate NS is a potent, clinically effective and well-tolerated intranasal corticosteroid with negligible systemic activity and which offers the convenience of once-daily dosing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943488     DOI: 10.1517/14656566.4.9.1579

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  Hay fever in adolescents and adults.

Authors:  Aziz Sheikh; Sukhmeet Singh Panesar; Sarah Salvilla; Sangeeta Dhami
Journal:  BMJ Clin Evid       Date:  2009-11-18

2.  The effect of combined medical treatment on quality of life in persistent allergic rhinitis.

Authors:  Emel Çadallı Tatar; Unzile Akpınar Sürenoğlu; Ali Ozdek; Güleser Saylam; Hakan Korkmaz
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-02-02

Review 3.  Mometasone furoate nasal spray: a review of safety and systemic effects.

Authors:  Myron Zitt; Teddy Kosoglou; James Hubbell
Journal:  Drug Saf       Date:  2007       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.